Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389591 · ClinicalTrials.gov registry record · Phase 1
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
A Phase 1 study of Recurrent Glioblastoma, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06389591 is a Phase 1 study of Recurrent Glioblastoma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 24 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06389591, a Phase 1 study of Recurrent Glioblastoma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
Conditions Studied
Interventions
- BIOLOGICAL pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)
- BIOLOGICAL RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Study Locations (1)
Florida
- UF Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06389591
The ClinicalTrials.gov registry entry for NCT06389591 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (65% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) is the first listed.
NCT06389591 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06389591 about?
NCT06389591 is a clinical study titled "RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)". This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
What is the current status of trial NCT06389591?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-12-02. Estimated completion is 2027-12-01.
What conditions does trial NCT06389591 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT06389591?
The interventions under investigation include: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) (BIOLOGICAL), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06389591?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06389591 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.